Cargando…
Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients
Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. The efficacy and safety have been demonstrated in clinical trials, but these...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564127/ https://www.ncbi.nlm.nih.gov/pubmed/32824992 http://dx.doi.org/10.3390/jcm9092684 |
_version_ | 1783595642840416256 |
---|---|
author | Tavecchio, Simona Angileri, Luisa Pozzo Giuffrida, Francesco Germiniasi, Francesca Marzano, Angelo Valerio Ferrucci, Silvia |
author_facet | Tavecchio, Simona Angileri, Luisa Pozzo Giuffrida, Francesco Germiniasi, Francesca Marzano, Angelo Valerio Ferrucci, Silvia |
author_sort | Tavecchio, Simona |
collection | PubMed |
description | Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. The efficacy and safety have been demonstrated in clinical trials, but these studies do not reflect conditions in daily practice and do not consider the different clinical manifestations of AD. Objectives: Analyzing the dupilumab activity in a real-world setting and comparing its efficacy on different AD phenotypes. Methods: We retrospectively evaluated 221 AD patients treated with dupilumab, stratified into six clinical phenotypes: classic, generalized eczema inflammatory and lichenoid patterns, prurigo, nummular eczema, and erythroderma. At baseline and at weeks 4, 16, and 52, the disease severity was assessed through the Eczema Area and Severity Index (EASI) and the quality of life was assessed through the Dermatology Life Quality Index (DLQI) questionnaire, Peak Pruritus Numerical Rating Scale (itch NRS), and Peak Sleep NRS. Results: We found a significant improvement after 16 weeks of treatment (p < 0.0001) in all six phenotypes for all the assessed scores mentioned above, persisting up to week 52. The best improvement was seen in the more severe phenotypes, particularly the erythrodermic one. Conclusions: The present study confirmed the efficacy and safety of dupilumab in the treatment of severe AD. Its strength was in the stratification of AD patients in six different phenotypes based on their clinical presentation, all of whom markedly improved in terms of both clinically evident and reported symptoms, as well as their quality of life. |
format | Online Article Text |
id | pubmed-7564127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75641272020-10-27 Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients Tavecchio, Simona Angileri, Luisa Pozzo Giuffrida, Francesco Germiniasi, Francesca Marzano, Angelo Valerio Ferrucci, Silvia J Clin Med Article Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. The efficacy and safety have been demonstrated in clinical trials, but these studies do not reflect conditions in daily practice and do not consider the different clinical manifestations of AD. Objectives: Analyzing the dupilumab activity in a real-world setting and comparing its efficacy on different AD phenotypes. Methods: We retrospectively evaluated 221 AD patients treated with dupilumab, stratified into six clinical phenotypes: classic, generalized eczema inflammatory and lichenoid patterns, prurigo, nummular eczema, and erythroderma. At baseline and at weeks 4, 16, and 52, the disease severity was assessed through the Eczema Area and Severity Index (EASI) and the quality of life was assessed through the Dermatology Life Quality Index (DLQI) questionnaire, Peak Pruritus Numerical Rating Scale (itch NRS), and Peak Sleep NRS. Results: We found a significant improvement after 16 weeks of treatment (p < 0.0001) in all six phenotypes for all the assessed scores mentioned above, persisting up to week 52. The best improvement was seen in the more severe phenotypes, particularly the erythrodermic one. Conclusions: The present study confirmed the efficacy and safety of dupilumab in the treatment of severe AD. Its strength was in the stratification of AD patients in six different phenotypes based on their clinical presentation, all of whom markedly improved in terms of both clinically evident and reported symptoms, as well as their quality of life. MDPI 2020-08-19 /pmc/articles/PMC7564127/ /pubmed/32824992 http://dx.doi.org/10.3390/jcm9092684 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tavecchio, Simona Angileri, Luisa Pozzo Giuffrida, Francesco Germiniasi, Francesca Marzano, Angelo Valerio Ferrucci, Silvia Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients |
title | Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients |
title_full | Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients |
title_fullStr | Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients |
title_full_unstemmed | Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients |
title_short | Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients |
title_sort | efficacy of dupilumab on different phenotypes of atopic dermatitis: one-year experience of 221 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564127/ https://www.ncbi.nlm.nih.gov/pubmed/32824992 http://dx.doi.org/10.3390/jcm9092684 |
work_keys_str_mv | AT tavecchiosimona efficacyofdupilumabondifferentphenotypesofatopicdermatitisoneyearexperienceof221patients AT angileriluisa efficacyofdupilumabondifferentphenotypesofatopicdermatitisoneyearexperienceof221patients AT pozzogiuffridafrancesco efficacyofdupilumabondifferentphenotypesofatopicdermatitisoneyearexperienceof221patients AT germiniasifrancesca efficacyofdupilumabondifferentphenotypesofatopicdermatitisoneyearexperienceof221patients AT marzanoangelovalerio efficacyofdupilumabondifferentphenotypesofatopicdermatitisoneyearexperienceof221patients AT ferruccisilvia efficacyofdupilumabondifferentphenotypesofatopicdermatitisoneyearexperienceof221patients |